Hypertrophic cardiomyopathy is associated with a high risk of thromboembolic events, necessitating accurate risk stratification and life-long anticoagulant therapy following any episode of atrial fibrillation.
Early identification of risk factors and accurate risk stratification for thromboembolism in HCM patients are crucial for timely preventive measures and aggressive management.
Hypertrophic cardiomyopathy (HCM) is an inherited cardiac disease, which has a marked heterogeneity in clinical expression, natural history, and prognosis. HCM is associated with a high prevalence of thromboembolic events (stroke and systemic embolic events), even if taking no account of atrial fibrillation (AF), leading to unexpected disability and death in patients of all ages. Several risk factors of thromboembolism such as AF, greater age, left atrial diameter, heart failure and others have been confirmed in patients with HCM. Conventional thromboembolic predictive models were estimated by several trials in HCM population but it turned out to be unsatisfactory. Based on those previous explorations, researchers tried to modify or develop novel models suitable for HCM population in thromboembolism prediction. In consideration of catastrophic advent events of thromboembolism, current guidelines have recommended life-long anticoagulant therapy after a single short AF. Therefore, early identification of risk factors for thromboembolism, accurate risk stratification, timely preventive measures and aggressive management may help to avoid serious adverse thromboembolic events in HCM population.
Liu et al. (Wed,) conducted a review in Hypertrophic Cardiomyopathy. Hypertrophic cardiomyopathy is associated with a high risk of thromboembolic events, necessitating accurate risk stratification and life-long anticoagulant therapy following any episode of atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: